Granules in green API project
Granules India and Greenko ZeroC have formed a strategic partnership to promote ‘integrated green pharmaceutical zones’. The first part will be a 40-hectare greenfield facility at Kakinada, Andhra Pradesh, for large-scale manufacturing of key starting materials, intermediates, APIs and fermentation-based products, including DCDA, PAP, paracetamol and metformin.
The site will cost about €225 million to build over five years and will be constructed in multiple phases, based on sustainability principles. Greenko ZeroC will supply carbon-free energy and “enable” green hydrogen and other chemical derivatives.
RELATED ARTICLES
Swiss CDMO Siegfried has inaugurated its new global R&D centre for drug substances at its site in Evionnaz.
Peptides CDMO AmbioPharm, has broken ground on a 650 m2, $28 million expansion project at its Shanghai manufacturing site. This is due to be complete in 2H 2025 and will produce over 8 tonnes/year of crude peptide.
Three CDMOs have separately announced expansions in their antibody-drug conjugate (ADC) manufacturing capabilities and capacity on opposite sides of the Atlantic.
Biosynth, which supplies critical raw materials and services for diagnostics, vaccines and pharmaceuticals, has officially opened its Biosynth Biological Technology site at Lifebay, a technology park in Suzhou, China.
At its latest Capital Markets Day, Merck KGaA said that it is “in a strong strategic position” to profit from medium-term growth opportunities in all three of its business sectors after a transitional year in 2023.
At CPHI in Milan in October, eight Indian CDMOs announced that they have formed a trade group to raise the profile of India’s drug services sector and make it a destination of choice.
